{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T21:41:56Z","timestamp":1771623716413,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,5]]},"DOI":"10.7759\/cureus.100836","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:57:56Z","timestamp":1767628676000},"source":"Crossref","is-referenced-by-count":1,"title":["Deep Venous Thrombosis Within Two Weeks of Initiating Oral Semaglutide (Rybelsus): A Case Report"],"prefix":"10.7759","author":[{"given":"Maamoun","family":"Alsermani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baraa","family":"Ali Alkahmous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arwa A","family":"Alhutayrashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fai S","family":"Alshalhoob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"abulrahman Almosaiteer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Aljubayri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assia","family":"Saleh Alwabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Sermani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref2","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: PIONEER 4 trial","volume":"321","author":"Davies M","year":"2019","unstructured":"Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: PIONEER 4 trial. JAMA. 2019, 321:1466-80.","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30074-7","article-title":"Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial","volume":"8","author":"Yabe D","year":"2020","unstructured":"Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, Inagaki N. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2020, 8:392-406. 10.1016\/S2213-8587(20)30074-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.039446","article-title":"Glucagon-like peptide-1 receptor agonists and risk of venous thromboembolism: a\u00a0systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Liu Y","year":"2025","unstructured":"Liu Y, He L, Han S, et al.. Glucagon-like peptide-1 receptor agonists and risk of venous thromboembolism: a\u00a0systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2025, 14:e039446. 10.1161\/JAHA.124.039446","journal-title":"J Am Heart Assoc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.06.020","article-title":"Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Chiang CH","year":"2025","unstructured":"Chiang CH, Chang YC, Yu CC, et al.. Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2025, 23:3527-39. 10.1016\/j.jtha.2025.06.020","journal-title":"J Thromb Haemost"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5339\/qmj.2024.75","article-title":"Portal vein thrombosis in a patient on semaglutide","volume":"2024","author":"Farooqi MF","year":"2024","unstructured":"Farooqi MF, Khan M, Muhammad AM, Agha A. Portal vein thrombosis in a patient on semaglutide. Qatar Med J. 2024, 2024:75. 10.5339\/qmj.2024.75","journal-title":"Qatar Med J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14990","article-title":"Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes","volume":"25","author":"Aroda VR","year":"2023","unstructured":"Aroda VR, Erhan U, Jelnes P, et al.. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes Obes Metab. 2023, 25:1385-97. 10.1111\/dom.14990","journal-title":"Diabetes Obes Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz323","article-title":"Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes","volume":"116","author":"Heuvelman VD","year":"2020","unstructured":"Heuvelman VD, Van Raalte DH, Smits MM. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc Res. 2020, 116:916-30. 10.1093\/cvr\/cvz323","journal-title":"Cardiovasc Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.15386\/mpr-1372","article-title":"Association between obesity and venous thromboembolism","volume":"93","author":"Hotoleanu C","year":"2020","unstructured":"Hotoleanu C. Association between obesity and venous thromboembolism. Med Pharm Rep. 2020, 93:162-8. 10.15386\/mpr-1372","journal-title":"Med Pharm Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/IMCRJ.S392338","article-title":"Extensive lower limb deep vein thrombosis provoked by gastroenteritis-induced dehydration: a case report for unusual precipitating factor","volume":"15","author":"Shbeer A","year":"2022","unstructured":"Shbeer A. Extensive lower limb deep vein thrombosis provoked by gastroenteritis-induced dehydration: a case report for unusual precipitating factor. Int Med Case Rep J. 2022, 15:713-8. 10.2147\/IMCRJ.S392338","journal-title":"Int Med Case Rep J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/440898-deep-venous-thrombosis-within-two-weeks-of-initiating-oral-semaglutide-rybelsus-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:57:57Z","timestamp":1767628677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/440898-deep-venous-thrombosis-within-two-weeks-of-initiating-oral-semaglutide-rybelsus-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.100836","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}